Advice
following a resubmission:
ferric maltol (Feraccru®) is not recommended for use within NHSScotland.
Indication under review: in adults for the treatment of iron deficiency.
Ferric maltol failed to demonstrate non-inferiority to an intravenous (IV) iron preparation, but was superior to placebo for correction of iron deficiency anaemia (IDA) in patients with inflammatory bowel disease (IBD).
The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.
Download detailed advice883KB (PDF)
Medicine details
- Medicine name:
- ferric maltol (Feraccru)
- SMC ID:
- SMC2500
- Indication:
For the treatment of iron deficiency in adults.
- Pharmaceutical company
- Norgine Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 16 January 2023